CA3234219A1 - Inhibitors of human immunodeficiency virus replication - Google Patents
Inhibitors of human immunodeficiency virus replication Download PDFInfo
- Publication number
- CA3234219A1 CA3234219A1 CA3234219A CA3234219A CA3234219A1 CA 3234219 A1 CA3234219 A1 CA 3234219A1 CA 3234219 A CA3234219 A CA 3234219A CA 3234219 A CA3234219 A CA 3234219A CA 3234219 A1 CA3234219 A1 CA 3234219A1
- Authority
- CA
- Canada
- Prior art keywords
- pharmaceutical composition
- formula
- compound
- weight
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163255056P | 2021-10-13 | 2021-10-13 | |
| US63/255,056 | 2021-10-13 | ||
| US202163257212P | 2021-10-19 | 2021-10-19 | |
| US63/257,212 | 2021-10-19 | ||
| PCT/IB2022/059780 WO2023062559A1 (en) | 2021-10-13 | 2022-10-12 | Inhibitors of human immunodeficiency virus replication |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3234219A1 true CA3234219A1 (en) | 2023-04-20 |
Family
ID=84044276
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3234219A Pending CA3234219A1 (en) | 2021-10-13 | 2022-10-12 | Inhibitors of human immunodeficiency virus replication |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240423985A1 (enExample) |
| EP (1) | EP4415685A1 (enExample) |
| JP (1) | JP2024535596A (enExample) |
| KR (1) | KR20240074850A (enExample) |
| AU (1) | AU2022362855B2 (enExample) |
| CA (1) | CA3234219A1 (enExample) |
| CL (1) | CL2024001073A1 (enExample) |
| IL (1) | IL311982A (enExample) |
| MX (1) | MX2024004551A (enExample) |
| WO (1) | WO2023062559A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202128648A (zh) * | 2019-10-04 | 2021-08-01 | 英商Ｖｉｉｖ醫療保健英國(Ｎｏ 5)有限公司 | 人類免疫不全病毒複製之抑制劑 |
| WO2025169059A1 (en) | 2024-02-05 | 2025-08-14 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3347352T (lt) * | 2016-08-19 | 2019-08-12 | Gilead Sciences, Inc. | Terapiniai junginiai, naudotini živ viruso infekcijos profilaktikai arba terapiniam gydymui |
| TW202024061A (zh) * | 2017-08-17 | 2020-07-01 | 美商基利科學股份有限公司 | Hiv蛋白質膜抑制劑之固體形式 |
| CA3103522C (en) * | 2018-07-16 | 2023-11-21 | Gilead Sciences, Inc. | Capsid inhibitors for the treatment of hiv |
| MA53973A (fr) | 2018-10-24 | 2022-02-09 | Viiv Healthcare Uk No 5 Ltd | Inhibiteurs de la réplication du virus de l'immunodéficience humaine |
| EP3986561B1 (en) | 2019-06-19 | 2024-02-14 | VIIV Healthcare UK (No.5) Limited | Pyrido[2,3-d]pyrimidine derivatives as inhibitors of human immunodeficiency virus replication |
| EP4135702B1 (en) * | 2020-04-15 | 2026-06-03 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
-
2022
- 2022-10-12 AU AU2022362855A patent/AU2022362855B2/en active Active
- 2022-10-12 EP EP22797493.8A patent/EP4415685A1/en active Pending
- 2022-10-12 IL IL311982A patent/IL311982A/en unknown
- 2022-10-12 WO PCT/IB2022/059780 patent/WO2023062559A1/en not_active Ceased
- 2022-10-12 US US18/700,402 patent/US20240423985A1/en active Pending
- 2022-10-12 JP JP2024522260A patent/JP2024535596A/ja active Pending
- 2022-10-12 MX MX2024004551A patent/MX2024004551A/es unknown
- 2022-10-12 KR KR1020247014899A patent/KR20240074850A/ko active Pending
- 2022-10-12 CA CA3234219A patent/CA3234219A1/en active Pending
-
2024
- 2024-04-11 CL CL2024001073A patent/CL2024001073A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024535596A (ja) | 2024-09-30 |
| US20240423985A1 (en) | 2024-12-26 |
| IL311982A (en) | 2024-06-01 |
| MX2024004551A (es) | 2024-06-26 |
| CL2024001073A1 (es) | 2024-10-04 |
| KR20240074850A (ko) | 2024-05-28 |
| WO2023062559A1 (en) | 2023-04-20 |
| AU2022362855B2 (en) | 2025-08-14 |
| AU2022362855A1 (en) | 2024-05-02 |
| EP4415685A1 (en) | 2024-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI814350B (zh) | 用於治療hiv之蛋白殼抑制劑 | |
| EP3266782B1 (en) | Fluorinated integrin antagonists | |
| AU2013358897B2 (en) | Pharmaceutical compositions | |
| ES2974541T3 (es) | Derivados de pirido[2,3-d]pirimidina como inhibidores de la replicación del virus de la inmunodeficiencia humana | |
| JP2010536797A (ja) | 眼の疾患または状態を治療するための製剤 | |
| US20240423985A1 (en) | Inhibitors of human immunodeficiency virus replication | |
| KR20250052453A (ko) | 헤르페스 바이러스에 대한 제약 조성물 | |
| US20170246118A1 (en) | Long acting pharmaceutical compositions | |
| KR20150139501A (ko) | 안과용 제형 | |
| WO2016172205A1 (en) | Managing ebola viral infections | |
| TW202227042A (zh) | 雙重鎮痛／消炎組合物、組合及其使用方法 | |
| CN118119376A (zh) | 人类免疫缺陷病毒复制的抑制剂 | |
| RU2618462C2 (ru) | Способ и улучшенная фармацевтическая композиция для ускорения трансдермальной доставки ингибитора pde-5 | |
| RU2660353C2 (ru) | Способ и улучшенная фармацевтическая композиция для ускорения трансдермальной доставки ингибитора pde-5 | |
| HK1248677B (en) | Fluorinated integrin antagonists | |
| HK40038956B (en) | Injectable composition | |
| HK1217696B (en) | Fluorinated integrin antagonists | |
| HK1117391A (en) | Formulations for ocular treatment | |
| HK1200365A1 (en) | Liquid formulations for treatment of diseases or conditions | |
| HK1198938B (en) | Method and improved pharmaceutical composition for enhancing transdermal delivery of pde-5 inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240923 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240923 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240923 |
|
| R00 | Party data change recorded |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R00-R113 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF ADDRESS OR METHOD OF CORRESPONDENCE REQUEST RECEIVED Effective date: 20250422 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250923 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250923 |
|
| R18 | Changes to party contact information recorded |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R18-R143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF ADDRESS REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260512 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260512 |